SEATTLE, March 27 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the Company will hold a conference call on Thursday evening to discuss the outcome of the U.S. Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee meeting for Provenge(R) (sipuleucel-T), the Company’s investigational active cellular immunotherapy under review for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.
Time: 7:30 pm ET / 6:30 pm CT / 5:30 pm MT / 4:30 pm PT Date: March 29, 2007 Dial-in: 1-800-289-0572 (domestic) or +1-913-981-5543 (international) Webcast: http://www.dendreon.com (homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 4486335. The replay will be available from 10:30 pm ET on Thursday, March 29th until 11:59 pm ET on Monday, April 2nd. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.
About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
SOURCE Dendreon Corporation
